摘要
Background Site A132Arg mutations potentially impair the affinity of isocitrate dehydrogenase 1 （IDH1） for its substrate isocitrate （ICT）, consequently reducing the production of a-ketoglutarate and leading to tumor growth through the induction of the hypoxia-inducible factor-1 （HIF-1） pathway. However, given that the roles of other active sites in IDH1 substrate binding remain unclear, we aimed to investigate IDH1 mutation pattern and its influence on enzyme function. Methods Fifteen IDH1 catalytic active site candidates were selected for in silico mutagenesis and protein homology modeling. Binding free energy of the IDH1/ICT complexes with single-site mutations was compared with that of the wild type. The affinity of 10 IDH1 catalytic active sites for the ICT substrate was further calculated. Results The IDH1 active site included seven residues from chain A （A77Thr, A94Ser, A100Arg, A132Arg, A109Arg, A275Asp, and A279Asp） and three residues from chain B （B214Thr, B212Lys, and B252Asp） that constituted the substrate ICT-binding site. These residues were located within 0.5 nm of ICT, indicating a potential interaction with the substrate. IDH1 changes of binding free energy （AE） suggested that the A132Arg residue from chain A contributes three hydrogen bonds to the ICT a-carboxyl and 13-carboxyl groups, while the other nine residues involved in ICT binding form only one or two hydrogen bonds. Amino acid substitutes at A132Arg, A109Arg, and B212Lys sites, had the greatest effect on enzyme affinity for its substrate. Conclusions Mutations at sites A132Arg, A109Arg, and B212Lys reduced IDH1 affinity for ICT, indicating these active sites may play a central role in substrate binding. Mutations at sites A77Thr, A94Ser, and A275Asp increased the affinity of IDH1 for ICT, which may enhance IDN1 catalytic activity. Mutant IDH1 proteins with higher catalytic activity than the wild-tvDe IDH1 could potentially be used as a novel qene therapy for qlioblastoma multiforme.
Background Site A132Arg mutations potentially impair the affinity of isocitrate dehydrogenase 1 （IDH1） for its substrate isocitrate （ICT）, consequently reducing the production of a-ketoglutarate and leading to tumor growth through the induction of the hypoxia-inducible factor-1 （HIF-1） pathway. However, given that the roles of other active sites in IDH1 substrate binding remain unclear, we aimed to investigate IDH1 mutation pattern and its influence on enzyme function. Methods Fifteen IDH1 catalytic active site candidates were selected for in silico mutagenesis and protein homology modeling. Binding free energy of the IDH1/ICT complexes with single-site mutations was compared with that of the wild type. The affinity of 10 IDH1 catalytic active sites for the ICT substrate was further calculated. Results The IDH1 active site included seven residues from chain A （A77Thr, A94Ser, A100Arg, A132Arg, A109Arg, A275Asp, and A279Asp） and three residues from chain B （B214Thr, B212Lys, and B252Asp） that constituted the substrate ICT-binding site. These residues were located within 0.5 nm of ICT, indicating a potential interaction with the substrate. IDH1 changes of binding free energy （AE） suggested that the A132Arg residue from chain A contributes three hydrogen bonds to the ICT a-carboxyl and 13-carboxyl groups, while the other nine residues involved in ICT binding form only one or two hydrogen bonds. Amino acid substitutes at A132Arg, A109Arg, and B212Lys sites, had the greatest effect on enzyme affinity for its substrate. Conclusions Mutations at sites A132Arg, A109Arg, and B212Lys reduced IDH1 affinity for ICT, indicating these active sites may play a central role in substrate binding. Mutations at sites A77Thr, A94Ser, and A275Asp increased the affinity of IDH1 for ICT, which may enhance IDN1 catalytic activity. Mutant IDH1 proteins with higher catalytic activity than the wild-tvDe IDH1 could potentially be used as a novel qene therapy for qlioblastoma multiforme.
